Antonino Polizzi

Antonino Polizzi

Auto-generated profile, based on publicly available information

Antonino Polizzi

University of Oxford

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Advances in Life Course Research
Verified
Journal Article
Closed access
APAntonino Polizzi
Antonino Polizzi
ESEmanuela Struffolino
Emanuela Struffolino
ZWZachary Van Winkle
Zachary Van Winkle

4 November 2024 in Population and Development Review
Verified
Journal Article
Open access
JDJennifer Beam Dowd
Jennifer Beam Dowd
APAntonino Polizzi
Antonino Polizzi
ATAndrea M. Tilstra
Andrea M. Tilstra
Steady and significant improvements in life expectancy have been a bright spot for human progress for the last century or more. Recently, this success has shown signs of faltering in some high‐income countries, where mortality improvements have slowed or even reversed since the early 2010s. Combined with the large mortality shock of the COVID‐19 pandemic, guaranteed forward progress feels less certain. We review mortality trends in high‐income countries since 2000 through the COVID‐19 pandemic. While deteriorating mortality in the United States has received the most attention, countries including the United Kingdom, Canada, the Netherlands, Greece, and Germany are also seeing slowdowns. Before COVID‐19, these slowdowns largely reflected stalling improvements in cardiovascular disease mortality and increases in deaths from external causes in young and midlife for the worst‐performing countries. We discuss prospects for the future of mortality in high‐income countries, including lingering impacts of the COVID‐19 pandemic, challenges and opportunities related to the obesity epidemic, and emerging reasons for both optimism and pessimism. While biological limits to increased life expectancy may eventually dominate long‐term trends, human‐made social factors are currently holding many countries back from already achievable best‐practice life expectancy and will be key to near‐term improvements.

19 December 2024 in PNAS Nexus
Verified
Journal Article
Open access
APAntonino Polizzi
Antonino Polizzi
LZLuyin Zhang
Luyin Zhang
STSergey Timonin
Sergey Timonin
AGAashish Gupta
Aashish Gupta
JDJennifer Beam Dowd
Jennifer Beam Dowd
JAJose Manuel Aburto
Jose Manuel Aburto
Worldwide, mortality was strongly affected by the COVID-19 pandemic, both directly through COVID-19 deaths and indirectly through changes in other causes of death. Here, we examine the impact of the pandemic on COVID-19 and non-COVID-19 mortality in 24 countries: Australia, Austria, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, England and Wales, Hungary, Japan, Latvia, Lithuania, The Netherlands, Northern Ireland, Poland, Russia, Scotland, South Korea, Spain, Sweden, Switzerland, and the United States. Using demographic decomposition methods, we compare age- and cause-specific contributions to changes in female and male life expectancy at birth in 2019–2020, 2020–2021, and 2021–2022 with those before the COVID-19 pandemic (2015–2019). We observe large life expectancy losses due to COVID-19 in most countries, usually followed by partial recoveries. Life expectancy losses due to cardiovascular disease (CVD) mortality were widespread during the pandemic, including in countries with substantial (Russia, Central and Eastern Europe, and the Baltic countries) and more modest (United States) improvements in CVD mortality before the pandemic. Many Anglo-Saxon countries, including Canada, Scotland, and the United States, continued their prepandemic trajectories of rising drug-related mortality. Most countries saw small changes in suicide mortality during the pandemic, while alcohol mortality increased and cancer mortality continued to decline. Patterns for other causes were more variable. By 2022, life expectancy had still not returned to prepandemic levels in several countries. Our results suggest important indirect effects of the pandemic on non-COVID-19 mortality through the consequences of COVID-19 infection, nonpharmaceutical interventions, and underreporting of COVID-19-related deaths.

18 December 2023 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
UGUrsula Gazeley
Ursula Gazeley
APAntonino Polizzi
Antonino Polizzi
JRJulio E Romero-Prieto
Julio E Romero-Prieto
JAJose Manuel Aburto
Jose Manuel Aburto
GRGeorges Reniers
Georges Reniers
VFVeronique Filippi
Veronique Filippi
Background: The lifetime risk of maternal death quantifies the probability that a 15-year-old girl will die of a maternal cause in her reproductive lifetime. Its intuitive appeal means it is a widely used summary measure for advocacy and international comparisons of maternal health. However, relative to mortality, women are at an even higher risk of experiencing life-threatening maternal morbidity called ‘maternal near miss’ (MNM) events—complications so severe that women almost die. As maternal mortality continues to decline, health indicators that include information on both fatal and non-fatal maternal outcomes are required. Methods: We propose a novel measure—the lifetime risk of MNM—to estimate the cumulative risk that a 15-year-old girl will experience a MNM in her reproductive lifetime, accounting for mortality between the ages 15 and 49 years. We apply the method to the case of Namibia (2019) using estimates of fertility and survival from the United Nations World Population Prospects along with nationally representative data on the MNM ratio. Results: We estimate a lifetime risk of MNM in Namibia in 2019 of between 1 in 40 and 1 in 35 when age-disaggregated MNM data are used, and 1 in 38 when a summary estimate for ages 15–49 years is used. This compares to a lifetime risk of maternal death of 1 in 142 and yields a lifetime risk of severe maternal outcome (MNM or death) of 1 in 30. Conclusions: The lifetime risk of MNM is an urgently needed indicator of maternal morbidity because existing measures (the MNM ratio or rate) do not capture the cumulative risk over the reproductive life course, accounting for fertility and mortality levels.

16 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
APAntonino Polizzi
Antonino Polizzi
JDJennifer Beam Dowd
Jennifer Beam Dowd

31 May 2024 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
APAntonino Polizzi
Antonino Polizzi
ATAndrea M Tilstra
Andrea M Tilstra
In a previous issue of PNAS Nexus, Bor et al. quantified the number of “missing Americans”—the deaths that would have been averted if the United States had experienced the mortality conditions of other wealthy nations. In 2019 alone, their estimates indicate that more than 100,000 individuals in reproductive ages (15–49 years) would have survived. The concept of the “missing Americans” is a valuable one, but here we argue that it is incomplete because it does not include children that would have been born to those who died an early death. We examine 3 indicators to assess the strength of the mortality–fertility nexus at the population level, showing that mortality more negatively affects birth counts in the United States than in other wealthy nations. Using the mortality conditions in other wealthy nations as a reference, we estimate that between 2010 and 2019 alone, approximately 200,000 children were not born in the United States due to the premature death of their potential mothers. Our findings highlight that improving morbidity and mortality among people of reproductive age—without compromising their reproductive autonomy—is critical in the United States.